MENU
OGN
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

OGN stock forecast, quote, news & analysis

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day... Show more

OGN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for OGN with price predictions
Aug 20, 2026

Momentum Indicator for OGN turns positive, indicating new upward trend

OGN saw its Momentum Indicator move above the 0 level on August 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned positive. In of the 74 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for OGN just turned positive on August 12, 2026. Looking at past instances where OGN's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 219 cases where OGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OGN broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.587) is normal, around the industry mean (19.325). P/E Ratio (17.615) is within average values for comparable stocks, (32.988). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.613). OGN has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.028). OGN's P/S Ratio (0.592) is slightly lower than the industry average of (4.226).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. OGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.

A.I.Advisor
published Dividends

OGN is expected to pay dividends on September 10, 2026

Organon & Co OGN Stock Dividends
A dividend of $0.02 per share will be paid with a record date of September 10, 2026, and an ex-dividend date of August 14, 2026. The last dividend of $0.02 was paid on June 11. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 204.88B. The market cap for tickers in the group ranges from 72.83K to 1.11T. LLY holds the highest valuation in this group at 1.11T. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 5%. NSRX experienced the highest price growth at 19%, while MDCX experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 78%. For the same stocks of the Industry, the average monthly volume growth was 74% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 30
P/E Growth Rating: 55
Price Growth Rating: 38
SMR Rating: 53
Profit Risk Rating: 61
Seasonality Score: -41 (-100 ... +100)
View a ticker or compare two or three
OGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Details
Industry
N/A
Address
30 Hudson Street
Phone
+1 551 430-6900
Employees
10000
Web
https://www.organon.com